Search Results 381-390 of 18370 for alopecia
Experienced resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If patient underwent major surgery or ...
All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4 grade =< 1 (except alopecia); certain ...
... alopecia or peripheral neuropathy. Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and endocrine ...
... alopecia and other non-clinically significant adverse events (AEs); The subject has active brain metastases or epidural disease; subjects with brain ...
... alopecia). Patients must not have had nitrosoureas or mitomycin C for 6 weeks prior to the initiation of study treatment. Radiation: Prior radiation therapy ...
Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy. 2 ...
Residual chronic toxicities of prior therapy ≤ Grade 2 (eg, peripheral neuropathy, residual alopecia) are allowed. Female subjects who are pre-menopausal ...
... alopecia) and/or in whom ≥30% of the bone marrow was irradiated. Patient has had major surgery ≤14 days prior to registration or has not recovered from ...
Uso de la espironolactona en dermatología: Acné, hidradenitis supurativa, alopecia femenina e hirsutismo. Actas Dermosifiliogr. 2020; doi: 10.1016/j.ad ...
Exceptions are alopecia, hypothyroidism, or type 1 diabetes mellitus controlled with medical intervention, and paronychia controlled with local intervention.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!